Drug repurposing, repositioning, and rescue all allow pharmaceutical companies to maintain or increase the lifecycle of drugs and decrease the expense of the full research and development process. In today's society, life science organizations not only develop strategies and methods to help find cures for diseases; they also utilize data from past clinical trials to uncover potential new indications to repurpose, reposition or rescue a drug. With more than 7,000 known diseases worldwide, drug repurposing provides an alternative route for companies to provide treatments to patients faster.
At our
2nd Strategic Partnership for Drug Repurposing Forum you will hear the latest indications for repurposing, rescuing and repositioning existing drugs to explore the newest innovations. Attendees will learn about the different resources available to them, including public-private partnerships, foundations, patient advocacy groups, universities and other funding partners. Come network and build partnerships with all stakeholders.
Top Five Reasons to Attend
- Engage in case studies and panel discussions on how to excel in searching for drug repurposing opportunities and uncover new indications for existing drugs
- Cover new methods in the pipeline by using innovative strategies to discover new therapeutic uses for existing molecules
- Identify new technologies used for the evaluation of repurposed drugs
- Explore how to develop strategic partnerships between the government, universities, patient advocacy groups, foundations, and sponsors
- Understand the FDA regulations (505b) for New Drug Applications, the legal framework and intellectual property laws surrounding drug repurposing
Speakers
- Pankaj Agarwal, Senior Fellow, Computational Biology, GLAXOSMITHKLINE
- Hassan Al-Ali, Ph.D., Research Assistant Professor, UNIVERSITY OF MIAMI, Chief Scientific Officer, TRUVITECH LLC
- Alex Aliper, President of European Operations, INSILICO MEDICINE
- David M. Aronoff, Director, Division of Infectious Diseases, Addison B. Scoville Jr. Chair in Medicine, Professor of Medicine, VANDERBILT UNIVERSITY
- Bobbie Austin, Program Officer, Drug Development Partnership Programs, NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES, NIH
- Bruce Bloom, CEO, CURES WITHIN REACH
- Bin Chen, Assistant Professor, Dept. of Pediatrics and Institute for Computational Health Sciences, UCSF
- Chitra Edwin, RAC Senior Vice President of Regulatory Affairs and Compliance, SPOTLIGHT INNOVATION
- Sean Evans, Associate Director, Business Development and Corporate Partnerships Johns Hopkins Technology Ventures, JOHNS HOPKINS UNIVERSITY
- Neal Farber, Chief Executive Officer and Director, NEUROHEALING PHARMACEUTICALS
- Brian Fisher, Vice President of Operations and Corporate Partnerships, STURGE-WEBER FOUNDATION
- Raymond K. Houck, President and CEO, THAR PHARMACEUTICALS
- Laura Kleiman, Scientific Research Director, cBio Center, DANA-FARBER CANCER INSTITUTE
- Daphna Laifenfeld, Ph.D., Senior Director, Personalized and Predictive Medicine, TEVA
- Zhicha Liu, Staff Fellow, FDA
- Jack Mycka, Global President, Chief Executive Officer, and Partner, MEDICAL MARKETING ECONOMICS, LLC
- Antoun Nabhan, CFO, ESTABLISHMENT LABS
- Aris Persidis, President, BIOVISTA
- Bernadette Siddiqi, Research Programs Officer, MICHAEL J. FOX FOUNDATION
- Heather Stone, Public Health Analyst, FDA
- Craig Wegner, Executive Director, Boston Head, Emerging Innovations, Scientific Partnering and Alliances, ASTRAZENECA PHARMACEUTICALS
- Stephen Wong, Chairman and Professor, Department of Systems Medicine and Bioengineering, and Chief Research Informatics Officer, HOUSTON METHODIST
Please fill in your name and email to receive the conference agenda of this event.
Conference Day One - Thursday, October 26, 2017
Conference Day Two - Friday, October 27, 2017
The agenda is available as PDF under downloads at the right side of the page.
Venue
Hyatt Regency Boston Harbor
101 Harborside Dr, 02128
Boston, MA, USA
Who Should Attend
This conference is designed for representatives from pharmaceutical, biotechnology and medical device organizations; patient organizations; and nonprofit foundations with responsibilities in the following areas:
- Drug Repurposing
- Indication Expansion
- Strategic Partnerships and Alliances
- Global Commercialization/Strategy
- Program and Portfolio Development
- Translational Medicine
- Strategy and Portfolio Solutions
- Corporate Strategy
- Market Access
- Asset Management
- Advanced Brand Strategies
- Research and Development
- Scientific/Clinical Development
- Regulatory Affairs
- Bioinformatics
- Big Data Analytics
- Patient Networks
This event is also of interest to professionals involved in:
- Clinical Operations/Clinical Outsourcing
- Trauma Therapeutics
- Drug Delivery/Discovery
- Product Development
- Clinical Operations
Venue
Hyatt Regency Boston Harbor101 Harborside Drive
Boston, MA 02128
To make reservations please call 888-421-1442 and request the negotiated rate for ExL’s October Meetings.
To make reservations online
Click HereThe group rate is available until October 4, 2017. Please book your room early as rooms available at this rate are limited.
